Frontline Afatinib in EGFR-Mutant NSCLC

preview_player
Показать описание
Lecia Sequist, MD, MPH, and Corey J. Langer, MD, discuss findings from the phase III LUX-Lung-3 and LUX-Lung-6 trials that explored frontline afatinib for patients with non-small cell lung cancer.
  1. OncLive
  2. cancer
  3. oncology
  4. Epidermal Growth Factor Receptor (Protein)
  5. Non-small Cell Lung Cancer (Disease Or Medical Condition)
  6. Afatinib
Рекомендации по теме
Frontline Afatinib in 0:04:09

Frontline Afatinib in EGFR-Mutant NSCLC

FDA Approval of 0:01:21

FDA Approval of Frontline Osimertinib in Frontline EGFR-Mutant NSCLC

Sequential treatment with 0:06:28

Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive NSCLC

Dr. West on 0:01:47

Dr. West on FDA Approval of Afatinib in NSCLC With Rare EGFR Mutations

DEBATE: Drug of 0:16:22

DEBATE: Drug of choice for exon 19 del EGFR mutant NSCLC - Afatinib

Phase III Data 0:01:45

Phase III Data Support Frontline Osimertinib in EGFR-Mutant Lung Cancers

Advances in Frontline 0:08:11

Advances in Frontline Therapy for EGFR+ NSCLC

EGFR mutation positive 0:23:10

EGFR mutation positive tumors: Treatment strategies in front line and at relapse

Afatinib in Patients 0:04:06

Afatinib in Patients With Uncommon EGFR Mutations

Frontline Therapy for 0:05:18

Frontline Therapy for EGFR Plus NSCLC: Osimertinib’s Impact

Front-line osimertinib significantly 0:05:06

Front-line osimertinib significantly lengthens overall survival in EGFR-mutation positive NSCLC

Afatinib Therapy for 0:03:47

Afatinib Therapy for Uncommon EGFR Alterations in NSCLC

Osimertinib For Uncommon 0:03:30

Osimertinib For Uncommon EGFR Mutations in NSCLC

Targeted treatment with 0:20:24

Targeted treatment with EGFR TKIs: Front line options

Dr. Chachoua on 0:01:25

Dr. Chachoua on Afatinib for Exon 19 Mutation in Lung Cancer

EGFR TKIs for 0:05:47

EGFR TKIs for Upfront Treatment of NSCLC

Frontline therapy for 0:17:36

Frontline therapy for EGFR-mutant NSCLC - Mary Jo Fidler

Strategies for Approaching 0:08:00

Strategies for Approaching Frontline Therapy in EGFR+ NSCLC

A Case of 0:05:55

A Case of EGFR-Mutant Non–Small Cell Lung Cancer

EGFR inhibitors in 0:18:06

EGFR inhibitors in mutation (+) patients: Current therapeutic strategies in the frontline setting

Front-line targeted therapy 0:17:55

Front-line targeted therapy for advanced EGFR-positive disease

Dr. Langer on 0:01:30

Dr. Langer on Afatinib for Advanced Non-Small Cell Lung Cancer

Emerging Data in 0:07:08

Emerging Data in EGFR-Mutant Lung Cancer

DEBATE: Drug of 0:13:26

DEBATE: Drug of choice for exon 19 del EGFR mutant NSCLC - Any EGFR TKI